Preclinical

#Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Lead discovery #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Early Validation: The difference between success and failure?

Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may not require… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Oncology #PCR #Preclinical #RNA #Screening #Stem cells #Therapeutics

The Microplate Market Past, Present and Future

The Microplate Market Past, Present and Future By Dr Peter Banks Microplates and the peripheral markets of liquid handling and detection technologies exist within almost all laboratories performing assays. This article discusses what, if any, are their growth expectations and whether there are new technologies on the horizon that could… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Lead discovery #Lead optimisation #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Toxicology

Predicting Transporter-mediated Drug-drug Interactions Based on in Vitro Cell Permeability Assays

Predicting Transporter-mediated Drug-drug Interactions Based on in Vitro Cell Permeability Assays By Dr Chris Bode Drugs may fail in clinical development or post-marketing for a variety of reasons: they may simply not be as effective as anticipated; poor pharmacokinetic properties may prevent them from reaching their intended target in therapeutic… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Bioengineering #Business #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Target validation #Toxicology

Natural Product Pharmaceuticals – The third generation

Natural Product Pharmaceuticals - The third generation By Dr Melanie McCullagh Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%) were second generation… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Biomarkers #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #RNA #Toxicology

Biomarker Signal Definition

Biomarker Signal Definition By Dr Gordon F. Kapke and Dr Nigel Brown Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding their associated business models as necessary. Companies need to improve success in late stage development, but what… Read More

#Archive

#Academic #Animal models #Business #Cell culture #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Molecular medicine #Pathology #Pharmacology #Preclinical #RNA #Screening #Stem cells #Toxicology

The Potential of High-resolution Human Immune Cell Assays to Aid the Pre-clinical to Clinical Transition of Drug Development Projects

The Potential of High-resolution Human Immune Cell Assays to Aid the Pre-clinical to Clinical Transition of Drug Development Projects By Dr Catherine A. Brady The effort to develop drugs that interact with the human immune system (whether by accident or design) has been dogged by a mismatch between the data… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Lead discovery #Lead optimisation #Preclinical #Regulatory #RNA

Outsourcing for Innovation Takes on New Meaning

Outsourcing for Innovation Takes on New Meaning By Richard Boehner Large pharmaceutical companies are moving quickly to outsource their drug discovery operations, predominantly to lower costs. This article argues that if outsourcing is done to capture value, ie developing and preserving intellectual property as a key competitive differentiation as well… Read More

#Archive

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Oncology #Pathology #Preclinical #RNA #Target validation #Toxicology #Translational #Translational chemistry

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics By Dr William E. Fogler Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Patent Law #PCR #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas

High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genomics #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Precision medicine #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers By Dr John Todd and Dr Sara J. Agee Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology. Advances in immunoassay technology,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Bioengineering #Business #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Oncology #Pharmokinetics #Preclinical #Screening #System biology #Systems biology #Therapeutics

Prediction versus Attrition in Drug Discovery & Development

Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #High throughput screening #Immunology #Pharmacology #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Challenges in Transferring Bioanalytical Methods

Challenges in Transferring Bioanalytical Methods By Dr Chris Beaver Drug development is arduous and expensive with any delay to market resulting in significant financial impact. Delays at any stage of the process cause challenges to programmes, however, some are easier to predict and plan for than others. Development of bioanalytical… Read More

#Archive

#Academic #ADME / Tox #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Growing Interest in Outsourcing Ion Channel Services

Growing Interest in Outsourcing Ion Channel Services By Dr John Comley Summer 2008 Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings. In the highly competitive area of cardiac safety hERG testing… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Orphan drugs #PCR #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Progress in the Implementation of Label-Free Detection – Cell-based assays

Progress in the Implementation of Label-Free Detection - Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec's recent Cell-Based Label-Free Detection Trends report. Uniquely all of these label-free offerings are plate-based and… Read More

#Archive

#Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Transcending Proteasome Inhibition for the Treatment of Cancer

Transcending Proteasome Inhibition for the Treatment of Cancer By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS). Specific pharmacological inhibition of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #System biology #Systems biology #Target validation

The Potential of Molecular Imaging for Drug Discovery & Development

The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More

#Archive